Combination therapy for advanced head and neck cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a new combination of two drugs for people with advanced head and neck cancer who cannot take standard platinum chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer (squamous cell carcinoma) that has come back or spread and cannot be cured with local treatments.
- You have not had chemotherapy before, or if you had induction or adjuvant treatment, it ended at least 6 months ago.
- You cannot take platinum-based chemotherapy because you are 70 or older, have hearing problems, or have reduced kidney function.
- You are in generally good health (able to care for yourself) and have at least one tumor that can be measured.
- Your blood counts and liver and kidney function are within acceptable ranges.
- You have not had other cancers in the last 3 years (except for certain skin or early-stage cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
This trial is testing a combination of two drugs (becotatug vedotin and pucotenlimab) given before surgery to shrink recurrent head and neck cancer that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this approach helps make the tumor removable and improves outcomes.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
This trial tests a new combination treatment for head and neck cancer. The treatment uses an investigational drug (becotatug vedotin) with an immunotherapy (a checkpoint inhibitor). The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new HNPCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.